Related Experiment Video
Updated: Aug 14, 2026
08:20
A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome
Published on: October 2, 2018
Multiphasic oral contraceptives. Efficacy and metabolic impact
The Journal of Reproductive Medicine
|January 1, 1987
Summary
New multiphasic oral contraceptives aim to improve efficacy and reduce side effects by varying progestin doses. Norethindrone formulations show the best results with minimal metabolic impact.
Area of Science:
- Reproductive Health
- Endocrinology
- Pharmacology
Background:
- Traditional oral contraceptives utilize fixed doses of steroids.
- Concerns exist regarding cardiovascular and metabolic side effects of oral contraceptives.
- Multiphasic formulations offer a potential strategy to mitigate these risks.
Purpose of the Study:
- To evaluate the efficacy and safety of new multiphasic oral contraceptives.
- To compare metabolic and cardiovascular effects of different oral contraceptive formulations.
- To identify oral contraceptive formulations with optimal risk-benefit profiles.
Main Methods:
- Review of existing literature on multiphasic oral contraceptives.
- Analysis of clinical trial data comparing fixed-dose and multiphasic formulations.
- Assessment of metabolic parameters (lipids, carbohydrates) and cardiovascular outcomes.
Main Results:
- Multiphasic oral contraceptives reduce total monthly steroid dose compared to fixed-dose options.
- Lower progestin doses in multiphasic formulations correlate with reduced cardiovascular complications.
- Norethindrone-containing multiphasic oral contraceptives demonstrate superior efficacy and minimal metabolic impact.
Conclusions:
- Multiphasic oral contraceptives offer an effective and safer alternative to fixed-dose preparations.
- Strategic progestin dose variation can enhance contraceptive safety profiles.
- Norethindrone multiphasics are recommended for their favorable efficacy and metabolic characteristics.
More Related Videos
Related Concept Videos
01:12First Pass Effect
Presystemic elimination, or the first-pass effect, is the metabolism of drugs that reduces their effective concentration at the site of action. Apart from the first-pass effect, the systemic bioavailability of the drug is also reduced by other factors, including incomplete absorption or chemical degradation of drugs.
Depending on the route of administration, drugs can be metabolized in the liver, intestine, lungs, and vasculature. Orally administered drugs are first absorbed through the...
Depending on the route of administration, drugs can be metabolized in the liver, intestine, lungs, and vasculature. Orally administered drugs are first absorbed through the...
01:24Factors Influencing Drug Absorption: Presystemic Elimination
The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary...
01:19Factors Affecting Drug Biotransformation: Biological
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...